J
John V. Duncia
Researcher at Bristol-Myers Squibb
Publications - 70
Citations - 4432
John V. Duncia is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Angiotensin II & Angiotensin receptor. The author has an hindex of 30, co-authored 70 publications receiving 4371 citations. Previous affiliations of John V. Duncia include DuPont.
Papers
More filters
Journal ArticleDOI
Identification of angiotensin II receptor subtypes
Andrew T. Chiu,William F. Herblin,Dale E. McCall,Robert John Ardecky,David J. Carini,John V. Duncia,Lori J. Pease,Pancras C. Wong,Ruth R. Wexler,Alexander L. Johnson,Pieter B.M.W.M. Timmermans +10 more
TL;DR: Two distinct subtypes of the angiotensin II receptor in the rat adrenal gland are demonstrated using radioligand binding and tissue section autoradiography and the discovery of two structurally dissimilar, nonpeptide compounds that show reciprocal selectivity for the two subtypes.
Patent
Angiotensin II receptor blocking imidazoles
David J. Carini,John V. Duncia +1 more
TL;DR: Substituted imidazoles such as ##STR1## are useful as angiotensin II blockers as mentioned in this paper, which have activity in treating hypertension and congestive heart failure.
Journal ArticleDOI
Three synthetic routes to a sterically hindered tetrazole. A new one-step mild conversion of an amide into a tetrazole
TL;DR: In this article, a tetrazole synthesis with a sterically hindered o-tetrazole group was described. But the synthesis was performed by three different routes, one of them employing a new tetrazoles synthesis.
Journal ArticleDOI
The discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives.
John V. Duncia,Andrew T. Chiu,David J. Carini,George B. Gregory,Alexander L. Johnson,William A. Price,Gregory J. Wells,Pancras C. Wong,Joseph C. Calabrese,Pieter B.M.W.M. Timmermans +9 more
TL;DR: The synthesis as well as the pharmacological activity of the compounds in this new series of AII receptor antagonists are presented, with a hypothesis suggesting the need for an additional acidic functionality to increase the lead's potency.
Patent
Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
TL;DR: Substituted imidazole angiotensin II blockers such as formula (I) can be administered in combination with diuretics for treatment of hypertension or in combination of a non-steroidal anti-inflammatory drug (NSAID) to prevent renal failure which can result from administration of an NSAID as discussed by the authors.